Movement Alert｜Regeneron Pharmaceuticals Falls 3.2% in Pre-Market Trading, Multiple Banks Cut Target Prices Amid Q2 Earnings Warning

Market Focus07-16 16:41

On July 16, Regeneron Pharmaceuticals fell 3.2% in pre-market trading, trading at $656.9/share. Market sentiment remained under pressure as multiple investment banks recently lowered their price targets on the company, compounded by a Q2 earnings pre-announcement warning.

On the news front, the company disclosed in an SEC filing that it expects both GAAP and non-GAAP diluted EPS for Q2 to decrease by approximately $1 versus expectations, raising investor concerns ahead of the July 30 earnings release. HSBC slashed its price target to $800 from $990, while RBC Capital trimmed its target to $696 from $707, maintaining a Sector Perform rating. Earlier, Citigroup downgraded the stock to Neutral with a target of $700, and Leerink Partners cut its rating to Market Perform with a $641 target.

The overhang from the May fianlimab Phase 3 trial failure in melanoma — which missed statistical significance despite a numeric 5.1-month improvement in median progression-free survival — continues to weigh on sentiment regarding the company's oncology pipeline competitiveness.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1149739226?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-16 16:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1149739226","market":"us","top_or_hot":-1,"title":"Movement Alert｜Regeneron Pharmaceuticals Falls 3.2% in Pre-Market Trading, Multiple Banks Cut Target Prices Amid Q2 Earnings Warning","media":"Market Focus","content":"<p><p>On July 16, Regeneron Pharmaceuticals fell 3.2% in pre-market trading, trading at $656.9/share. Market sentiment remained under pressure as multiple investment banks recently lowered their price targets on the company, compounded by a Q2 earnings pre-announcement warning.</p><p>On the news front, the company disclosed in an SEC filing that it expects both GAAP and non-GAAP diluted EPS for Q2 to decrease by approximately $1 versus expectations, raising investor concerns ahead of the July 30 earnings release. HSBC slashed its price target to $800 from $990, while RBC Capital trimmed its target to $696 from $707, maintaining a Sector Perform rating. Earlier, Citigroup downgraded the stock to Neutral with a target of $700, and Leerink Partners cut its rating to Market Perform with a $641 target.</p><p>The overhang from the May fianlimab Phase 3 trial failure in melanoma — which missed statistical significance despite a numeric 5.1-month improvement in median progression-free survival — continues to weigh on sentiment regarding the company's oncology pipeline competitiveness.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Regeneron Pharmaceuticals Falls 3.2% in Pre-Market Trading, Multiple Banks Cut Target Prices Amid Q2 Earnings Warning</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Regeneron Pharmaceuticals Falls 3.2% in Pre-Market Trading, Multiple Banks Cut Target Prices Amid Q2 Earnings Warning\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-16 16:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 16, Regeneron Pharmaceuticals fell 3.2% in pre-market trading, trading at $656.9/share. Market sentiment remained under pressure as multiple investment banks recently lowered their price targets on the company, compounded by a Q2 earnings pre-announcement warning.</p><p>On the news front, the company disclosed in an SEC filing that it expects both GAAP and non-GAAP diluted EPS for Q2 to decrease by approximately $1 versus expectations, raising investor concerns ahead of the July 30 earnings release. HSBC slashed its price target to $800 from $990, while RBC Capital trimmed its target to $696 from $707, maintaining a Sector Perform rating. Earlier, Citigroup downgraded the stock to Neutral with a target of $700, and Leerink Partners cut its rating to Market Perform with a $641 target.</p><p>The overhang from the May fianlimab Phase 3 trial failure in melanoma — which missed statistical significance despite a numeric 5.1-month improvement in median progression-free survival — continues to weigh on sentiment regarding the company's oncology pipeline competitiveness.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"REGN","symbol_name":"再生元制药公司","start_time":0,"source_url":"","article_id":"1149739226","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1149739226","pubTimestamp":1784191290,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 16, Regeneron Pharmaceuticals fell 3.2% in pre-market trading, trading at $656.9/share. Market sentiment remained under pressure as multiple investment banks recently lowered their price...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"REGN":"再生元制药公司"},"translate_title":"走势警报|再生元制药盘前交易下跌 3.2%，多家银行因第二季度盈利预警下调目标价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REGN":1},"content_text":"On July 16, Regeneron Pharmaceuticals fell 3.2% in pre-market trading, trading at $656.9/share. Market sentiment remained under pressure as multiple investment banks recently lowered their price targets on the company, compounded by a Q2 earnings pre-announcement warning.On the news front, the company disclosed in an SEC filing that it expects both GAAP and non-GAAP diluted EPS for Q2 to decrease by approximately $1 versus expectations, raising investor concerns ahead of the July 30 earnings release. HSBC slashed its price target to $800 from $990, while RBC Capital trimmed its target to $696 from $707, maintaining a Sector Perform rating. Earlier, Citigroup downgraded the stock to Neutral with a target of $700, and Leerink Partners cut its rating to Market Perform with a $641 target.The overhang from the May fianlimab Phase 3 trial failure in melanoma — which missed statistical significance despite a numeric 5.1-month improvement in median progression-free survival — continues to weigh on sentiment regarding the company's oncology pipeline competitiveness.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1149739226","isCrawlerRequest":true}